![news aktuell GmbH](/data/images/public/3194838/3571207/19eb2a1e-0867-4b3c-b80d-06fd8186aa3f-w_360_h_52.png)
Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences12.8.2024 09:00:00 CEST | news aktuell GmbH
Tübingen, Germany, August 12, 2024 Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August 20–22, and at the 36th World Congress of Audiology from September 19–22, 2024.